Quickstart Highlights
This stacked protocol combines CJC-1295 NO DAC (Modified GRF 1–29), a short-acting GHRH analog that produces a clean, pulsatile GH release, with Ipamorelin, a selective ghrelin-receptor agonist that triggers GH pulses with minimal ACTH, cortisol or prolactin release. Dosed together at bedtime, the two act on complementary receptors to amplify the body’s own nocturnal GH pulse while preserving normal feedback.
- CJC-1295 NO DAC (10 mg vial): Add 2.0 mL bacteriostatic water → 5 mg/mL; inject once daily at bedtime.
- Ipamorelin (10 mg vial): Add 2.0 mL bacteriostatic water → 5 mg/mL; inject once daily at bedtime, immediately after the CJC-1295 NO DAC dose.
- Easy measuring: at 5 mg/mL, 1 unit = 50 mcg for both peptides on a U-100 insulin syringe (100 mcg = 2 units; 200 mcg = 4 units).
- Typical range: 100–300 mcg of each per injection; start at 100 mcg and titrate to 200 mcg.
- Cycle: 8–12 weeks on, then 4 weeks off.
- Storage: Lyophilized: 2–8 °C (35.6–46.4 °F) or frozen; reconstituted: 2–8 °C (35.6–46.4 °F); use within 3–4 weeks.
Dosing & Reconstitution Guide
CJC-1295 NO DAC (10 mg Vial) — Subcutaneous, Once Daily
Reconstitution: 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) → 50 mcg per unit
| Phase | Daily Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg (0.1 mg) | 2 units (0.02 mL) | Once daily at bedtime |
| Weeks 3–4 (Titration) | 150 mcg (0.15 mg) | 3 units (0.03 mL) | Once daily at bedtime |
| Weeks 5–12 (Maintenance) | 200 mcg (0.2 mg) | 4 units (0.04 mL) | Once daily at bedtime |
| Advanced (Optional) | 300 mcg (0.3 mg) | 6 units (0.06 mL) | Once daily, or 100 mcg 2–3×/day fasted |
Note: At 5 mg/mL, each 10 mg vial provides 50 doses of 200 mcg (about 7 weeks) before preparation and delivery losses. Because reconstituted peptide is best used within 3–4 weeks, expect to open a fresh vial around the 4-week mark rather than running one vial to empty.
CJC-1295 NO DAC Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming or a direct stream onto the powder.
- Gently swirl/roll until fully dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Ipamorelin (10 mg Vial) — Subcutaneous, Once Daily
Reconstitution: 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) → 50 mcg per unit
| Phase | Daily Dose (mcg / mg) | Units (mL) per Injection | Frequency |
|---|---|---|---|
| Weeks 1–2 (Initiation) | 100 mcg (0.1 mg) | 2 units (0.02 mL) | Once daily at bedtime |
| Weeks 3–4 (Titration) | 150 mcg (0.15 mg) | 3 units (0.03 mL) | Once daily at bedtime |
| Weeks 5–12 (Maintenance) | 200 mcg (0.2 mg) | 4 units (0.04 mL) | Once daily at bedtime |
| Advanced (Optional) | 300 mcg (0.3 mg) | 6 units (0.06 mL) | Once daily, or 100 mcg 2–3×/day fasted |
For ≤10-unit (≤0.10 mL) administrations, 30- or 50-unit insulin syringes improve readability.
Ipamorelin Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label with date and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Combined Stack Schedule — Standard Approach
| Week | CJC-1295 NO DAC (Daily, bedtime) | Ipamorelin (Daily, bedtime) |
|---|---|---|
| Weeks 1–2 | 100 mcg (2 units) | 100 mcg (2 units) |
| Weeks 3–4 | 150 mcg (3 units) | 150 mcg (3 units) |
| Weeks 5–12 | 200 mcg (4 units) | 200 mcg (4 units) |
| Weeks 13–16 (Off) | No dose | No dose |
Timing: Both peptides are administered within a few minutes of each other, 30–60 minutes before bed on an empty stomach, so that the GHRH signal (CJC-1295 NO DAC) and the ghrelin-receptor signal (Ipamorelin) coincide with the natural nocturnal GH pulse. Avoid food, and particularly carbohydrates or fats, for 1–2 hours before dosing. Users who add a second or third dose typically place it on waking or before training, also fasted.
Important: This guide is for educational purposes only and is not medical advice. For research use only. Not for human consumption.
Supplies Needed
Plan based on an 8–16 week stacked protocol at standard dosing (200 mcg of each peptide once daily at maintenance, two separate injections per day).
- CJC-1295 NO DAC Vials (10 mg each):
- 8 weeks (56 days, ~11 mg total) → 2 vials
- 12 weeks (84 days, ~17 mg total) → 2 vials (3 if a fresh vial is opened every 4 weeks)
- 16 weeks (112 days, ~22 mg total) → 3 vials
- Ipamorelin Vials (10 mg each):
- 8 weeks (56 days, ~11 mg total) → 2 vials
- 12 weeks (84 days, ~17 mg total) → 2 vials (3 if a fresh vial is opened every 4 weeks)
- 16 weeks (112 days, ~22 mg total) → 3 vials
- Insulin Syringes (U-100):
- Per week: 7 (CJC-1295 NO DAC) + 7 (Ipamorelin) = 14 syringes
- 8 weeks: 112 syringes
- 12 weeks: 168 syringes
- 16 weeks: 224 syringes
- All doses in this protocol are ≤10 units, so 30- or 50-unit syringes improve accuracy.
- Bacteriostatic Water (30 mL bottles):
- 8 weeks: 4 vials × 2 mL = 8 mL → 1 × 30 mL bottle
- 12 weeks: 4–6 vials × 2 mL = 8–12 mL → 1 × 30 mL bottle
- 16 weeks: 6 vials × 2 mL = 12 mL → 1 × 30 mL bottle
- Alcohol Swabs:
- Per week: ~28 swabs (2 per injection × 14 injections)
- 8 weeks: 224 swabs → 3 × 100-count boxes
- 12 weeks: 336 swabs → 4 × 100-count boxes
- 16 weeks: 448 swabs → 5 × 100-count boxes
Protocol Overview
Concise summary of the stacked GH secretagogue regimen.
- Goal: Amplify endogenous, pulsatile GH and IGF-1 secretion through the GHRH and ghrelin-receptor pathways simultaneously.
- Schedule: CJC-1295 NO DAC + Ipamorelin once daily at bedtime for 8–12 weeks, then 4 weeks off.
- CJC-1295 NO DAC Dose: 100–300 mcg per injection (standard maintenance: 200 mcg).
- Ipamorelin Dose: 100–300 mcg per injection (standard maintenance: 200 mcg).
- Frequency: Once nightly is the entry point; 2–3 fasted doses per day is the advanced option.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid freeze–thaw cycles.
Dosing Protocol
Suggested approach for the stacked regimen.
- Start: 100 mcg (2 units) of each peptide once daily at bedtime for Weeks 1–2.
- Titrate: Increase both to 150 mcg (3 units) in Weeks 3–4 and 200 mcg (4 units) from Week 5, as tolerated.
- Advanced option: 300 mcg (6 units) of each at bedtime, or 100 mcg of each 2–3 times daily on an empty stomach.
- Timing: 30–60 minutes before bed, fasted, to align with natural nocturnal GH release.
- Cycle Length: 8–12 weeks on, then 4 weeks off; a 16-week cycle is the upper limit before a break.
- Injection Sites: Rotate abdomen, thighs, and upper arms; use a separate syringe for each peptide.
Storage Instructions
Proper storage preserves peptide integrity and efficacy.
- Lyophilized (dry powder): Refrigerate at 2–8 °C (35.6–46.4 °F) for short-term storage; freeze at −20 °C (−4 °F) or colder for long-term storage.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 3–4 weeks.
- Allow vials to reach room temperature before opening to minimize condensation uptake.
- Avoid repeated freeze–thaw cycles of reconstituted solutions.
Important Notes
Practical considerations for consistency and safety.
- Use a new sterile insulin syringe for each injection; dispose in a sharps container.
- Rotate injection sites systematically (abdomen, thighs, upper arms) to reduce local irritation.
- Inject slowly; wait a few seconds before withdrawing the needle.
- Dose on an empty stomach: food, especially carbohydrates and fats, blunts the GH pulse from both peptides.
- Keep CJC-1295 NO DAC and Ipamorelin in separate vials; do not pre-mix in the vial. Drawing both into one syringe immediately before injection is common practice but is not required.
- Log each dose so that titration steps and the off-cycle date are tracked.
How This Works
CJC-1295 NO DAC (Modified GRF 1–29) is a 29-amino-acid GHRH analog with four substitutions that protect it from rapid enzymatic breakdown. Without the Drug Affinity Complex, its half-life is roughly 30 minutes, so each injection produces a single, physiologic GH pulse rather than the sustained elevation seen with the DAC form. Ipamorelin is a selective growth hormone secretagogue that activates the ghrelin receptor (GHSR) to trigger a rapid GH pulse without significantly affecting ACTH, cortisol, or prolactin. Because the GHRH receptor and the ghrelin receptor act through different second-messenger systems in the same somatotroph cells, stimulating both at once produces a larger GH pulse than either agent alone, while the pituitary’s normal somatostatin feedback remains intact.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature on GH secretagogues.
- Body composition: GH secretagogues have demonstrated improvements in lean mass and reductions in fat mass in clinical studies.
- Pulsatile, physiologic GH release: The NO DAC form does not produce the multi-day GH and IGF-1 elevation of CJC-1295 DAC, which is why it is dosed daily.
- Selectivity: Ipamorelin does not significantly increase cortisol or ACTH at typical doses.
- Tolerability: Both peptides were well tolerated in human studies, with transient injection-site reactions being the most common adverse effect.
- Flushing and warmth for a few minutes after the CJC-1295 NO DAC injection, water retention, mild headache, and transient numbness or tingling have been reported with GH-elevating compounds.
Lifestyle Factors
Complementary strategies for optimal outcomes.
- Pair with a balanced, protein-forward diet tailored to individual energy and recovery needs.
- Combine resistance training and aerobic activity to support anabolic adaptations.
- Prioritize 7–9 hours of quality sleep; GH secretion peaks during deep sleep.
- Manage stress and avoid chronic caloric restriction, which can blunt GH response.
Injection Technique
General subcutaneous guidance from clinical best-practice resources.
- Clean the vial stopper and skin with alcohol; allow to dry completely.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue.
- Do not aspirate for subcutaneous injections; inject slowly and steadily.
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy.
- Limit each injection to ≤1 mL; split larger volumes into separate injections.
Recommended Source
Product reference: CJC-1295 NO DAC 10 mg and Ipamorelin 10 mg, supplied in separate vials.
Why Amino Labs?
- High-purity (≥99% HPLC), third-party-tested lots with batch COAs.
- Consistent, ISO-aligned handling and documentation.
- Reliable fulfillment to maintain cold-chain integrity.
CJC-1295 NO DAC 10 mg at Amino Labs | Ipamorelin 10 mg at Amino Labs
Important Note
This content is intended for therapeutic educational purposes only and does not constitute medical advice, diagnosis, or treatment.